Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “OVID THERAPEUTICS INC.”

48 pharma patents match "OVID THERAPEUTICS INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 48
Index total 30,257
Page 2 / 2

Quick answer

This filtered view shows 48 pharmaceutical patents matching "OVID THERAPEUTICS INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

48 results for “OVID THERAPEUTICS INC.” · 30,257 patents in full index Clear search

  1. US 10736894

    Methods of treating developmental syndromes with PDE10A inhibitors

    OVID THERAPEUTICS INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  2. US 10653652

    Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction

    OVID THERAPEUTICS INC. · Granted May 19, 2020 · Expires May 14, 2040

    granted
  3. US 10603308

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. · Granted Mar 31, 2020 · Expires Mar 26, 2040

    granted
  4. US 10493069

    Methods of treating behavioral syndromes using pipradrol

    OVID THERAPEUTICS INC. · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted
  5. US 10426746

    Methods of treating developmental disorders with biguanides

    OVID THERAPEUTICS INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  6. US 10420773

    Methods of treating developmental disorders and/or seizure disorders with etifoxine

    OVID THERAPEUTICS INC. · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  7. US 10363246

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted
  8. US 10265300

    Methods of treating seizure disorders

    OVID THERAPEUTICS INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted
  9. US 10195165

    Methods of treating Prader-Willi syndrome

    OVID THERAPEUTICS INC. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  10. US 10188635

    Use of gaboxadol in the treatment of tinnitus

    OVID THERAPEUTICS INC. · Granted Jan 29, 2019 · Expires Jan 24, 2039

    granted
  11. US 10123979

    Methods of treating developmental disorders with biguanides

    OVID THERAPEUTICS INC. · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  12. US 10111865

    Methods of sedation during critical care treatment

    OVID THERAPEUTICS INC. · Granted Oct 30, 2018 · Expires Oct 25, 2038

    granted
  13. US 10071083

    Use of gaboxadol in the treatment of tinnitus

    OVID THERAPEUTICS INC. · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted
  14. US 9913833

    Methods of treating developmental disorders using pipradrol

    OVID THERAPEUTICS INC. · Granted Mar 13, 2018 · Expires Mar 8, 2038

    granted
  15. US 9827233

    Methods of treating behavioral syndromes using pipradrol

    OVID THERAPEUTICS INC. · Granted Nov 28, 2017 · Expires Nov 23, 2037

    granted
  16. US 9801864

    Methods of increasing tonic inhibition and treating secondary insomnia

    OVID THERAPEUTICS INC. · Granted Oct 31, 2017 · Expires Oct 26, 2037

    granted
  17. US 9744159

    Methods of treatment Rett syndrome

    OVID THERAPEUTICS INC. · Granted Aug 29, 2017 · Expires Aug 24, 2037

    granted
  18. US 9717716

    Methods of sedation during critical care treatment

    OVID THERAPEUTICS INC. · Granted Aug 1, 2017 · Expires Jul 27, 2037

    granted
  19. US 9682069

    Methods of treating Dravet syndrome

    OVID THERAPEUTICS INC. · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted
  20. US 9610261

    Methods of treating Prader-Willi Syndrome

    OVID THERAPEUTICS INC. · Granted Apr 4, 2017 · Expires Mar 30, 2037

    granted
  21. US 9446028

    Methods of increasing tonic inhibition and treating fragile X syndrome and angelman syndrome

    OVID THERAPEUTICS INC. · Granted Sep 20, 2016 · Expires Sep 15, 2036

    granted
  22. US 9399034

    Methods of sedation during critical care treatment

    OVID THERAPEUTICS INC. · Granted Jul 26, 2016 · Expires Jul 21, 2036

    granted
  23. US 9351968

    Methods of treating developmental disorders using pipradrol

    OVID THERAPEUTICS INC. · Granted May 31, 2016 · Expires May 26, 2036

    granted
  24. US 9339495

    Methods of increasing tonic inhibition and treating secondary insomnia

    OVID THERAPEUTICS INC. · Granted May 17, 2016 · Expires May 12, 2036

    granted